3.02
price down icon0.66%   -0.02
after-market 시간 외 거래: 3.02
loading
전일 마감가:
$3.04
열려 있는:
$3.02
하루 거래량:
215.73K
Relative Volume:
0.63
시가총액:
$208.34M
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-9.7419
EPS:
-0.31
순현금흐름:
$-31.85M
1주 성능:
-1.95%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+88.75%
1일 변동 폭
Value
$2.86
$3.05
1주일 범위
Value
$2.86
$3.15
52주 변동 폭
Value
$0.97
$4.00

트레비 테라퓨틱스 Stock (TRVI) Company Profile

Name
명칭
Trevi Therapeutics Inc
Name
전화
203-304-2499
Name
주소
195 CHURCH STREET, NEW HAVEN, CT
Name
직원
26
Name
트위터
@TreviThera
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
TRVI's Discussions on Twitter

트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-04-12 개시 B. Riley Securities Buy
2022-11-22 개시 SVB Leerink Outperform
2019-06-03 개시 BMO Capital Markets Outperform
2019-06-03 개시 Needham Buy
2019-06-03 개시 SVB Leerink Outperform
2019-06-03 개시 Stifel Buy
모두보기

트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스

pulisher
Nov 04, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Result - GuruFocus.com

Nov 04, 2024
pulisher
Oct 31, 2024

Trevi Therapeutics (TRVI) Set to Announce Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - StreetInsider.com

Oct 30, 2024
pulisher
Oct 30, 2024

Trevi Therapeutics Adds Clinical Development Expertise in Chroni - GuruFocus.com

Oct 30, 2024
pulisher
Oct 23, 2024

Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc. - Yahoo Finance

Oct 23, 2024
pulisher
Oct 22, 2024

Trevi Therapeutics shares retain buy rating on Haduvio prospects By Investing.com - Investing.com UK

Oct 22, 2024
pulisher
Oct 22, 2024

Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

Trevi Therapeutics completes enrollment for Phase 2a trial - Investing.com

Oct 21, 2024
pulisher
Oct 21, 2024

Trevi Therapeutics completes enrollment for Phase 2a trial By Investing.com - Investing.com Australia

Oct 21, 2024
pulisher
Oct 21, 2024

Trevi Therapeutics, Inc. Completes Enrollment in the Phase 2A RIVER Trial of Haduvio - Marketscreener.com

Oct 21, 2024
pulisher
Oct 21, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough - Citizentribune

Oct 21, 2024
pulisher
Oct 19, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 19, 2024
pulisher
Oct 18, 2024

TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail

Oct 18, 2024
pulisher
Oct 18, 2024

Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings - MarketBeat

Oct 18, 2024
pulisher
Oct 15, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Citizentribune

Oct 15, 2024
pulisher
Oct 09, 2024

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: - GuruFocus.com

Oct 09, 2024
pulisher
Oct 08, 2024

Oppenheimer maintains Outperform on Trevi Therapeutics on Haduvio potential By Investing.com - Investing.com Canada

Oct 08, 2024
pulisher
Oct 07, 2024

Trevi Therapeutics' (TRVI) Buy Rating Reaffirmed at B. Riley - MarketBeat

Oct 07, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics reports progress in clinical trials - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at Needham & Company LLC - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi updates on clinical progress for chronic cough treatment - The Pharma Letter

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics reports progress in clinical trials By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs - Marketscreener.com

Oct 04, 2024
pulisher
Oct 04, 2024

Trevi Therapeutics hits 50% enrollment in IPF cough study By Investing.com - Investing.com South Africa

Oct 04, 2024
pulisher
Oct 03, 2024

Trevi Therapeutics hits 50% enrollment in IPF cough study - Investing.com India

Oct 03, 2024
pulisher
Oct 03, 2024

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program - Kilgore News Herald

Oct 03, 2024
pulisher
Sep 30, 2024

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer - The Malaysian Reserve

Sep 30, 2024
pulisher
Sep 27, 2024

President & CEO GOOD JENNIFER L sale 4,219 shares of Trevi Therapeutics Inc [TRVI] - Knox Daily

Sep 27, 2024
pulisher
Sep 26, 2024

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024 - StockTitan

Sep 26, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Purchases 600,000 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Financial Health Report: Trevi Therapeutics Inc (TRVI)’s Ratios Tell a Tale - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Ally Bridge Group NY LLC Invests $4.40 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Taking the lead: Trevi Therapeutics Inc (TRVI) - SETE News

Sep 23, 2024
pulisher
Sep 21, 2024

Trevi Therapeutics (TRVI) 10K Form and SEC Filings 2024 - MarketBeat

Sep 21, 2024
pulisher
Sep 19, 2024

Traws Pharma Inc. (TRAW) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Sep 19, 2024
pulisher
Sep 18, 2024

Portage Biotech (PRTG): Wild Ride Continues, But Uncertainty Looms - BP Journal

Sep 18, 2024
pulisher
Sep 18, 2024

Tourmaline Bio (NASDAQ:TRML) Shares Up 3.9% - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

UChicago Medicine Patient First in the World to Re | Newswise - Newswise

Sep 18, 2024
pulisher
Sep 17, 2024

Traws Pharma Announces Stock Split, Share Adjustments, and Growth Strategy - TipRanks

Sep 17, 2024
pulisher
Sep 17, 2024

UChicago Medicine patient first in the world to receive ulcerative colitis drug since FDA approval - UChicago Medicine

Sep 17, 2024
pulisher
Sep 17, 2024

Traws Pharma, Inc. Announces Special Shareholders Meeting Results - StockTitan

Sep 17, 2024
pulisher
Sep 17, 2024

Taking a Closer Look At Trevi Therapeutics Inc (TRVI) Following Its Recent Trade - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

trivago (NASDAQ:TRVG) Sees Large Growth in Short Interest - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

FDA Approves Tremfya for Ulcerative Colitis - Physician's Weekly

Sep 17, 2024
pulisher
Sep 15, 2024

Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 - Quantisnow

Sep 15, 2024
pulisher
Sep 15, 2024

trivago (NASDAQ:TRVG) Short Interest Up 16.9% in August - MarketBeat

Sep 15, 2024
pulisher
Sep 11, 2024

Trevi Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.12) Per Share, Leerink Partnrs Forecasts (NASDAQ:TRVI) - MarketBeat

Sep 11, 2024
pulisher
Sep 10, 2024

Trevi Therapeutics, Inc. Expected to Earn Q1 2025 Earnings of ($0.11) Per Share (NASDAQ:TRVI) - MarketBeat

Sep 10, 2024
pulisher
Sep 10, 2024

Leerink Partnrs Upgrades Trevi Therapeutics (NASDAQ:TRVI) to "Strong-Buy" - MarketBeat

Sep 10, 2024

트레비 테라퓨틱스 (TRVI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

트레비 테라퓨틱스 주식 (TRVI) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
GOOD JENNIFER L
President & CEO
Sep 09 '24
Option Exercise
1.43
1,840
2,631
215,153
GOOD JENNIFER L
President & CEO
Sep 06 '24
Sale
3.03
4,219
12,784
213,313
GOOD JENNIFER L
President & CEO
Sep 09 '24
Sale
3.04
1,840
5,587
213,313
GOOD JENNIFER L
President & CEO
Sep 05 '24
Option Exercise
1.43
40,277
57,596
253,590
GOOD JENNIFER L
President & CEO
Sep 04 '24
Option Exercise
1.43
10,981
15,703
224,294
GOOD JENNIFER L
President & CEO
Sep 03 '24
Option Exercise
1.43
3,863
5,524
217,176
GOOD JENNIFER L
President & CEO
Sep 05 '24
Sale
3.11
40,277
125,310
213,313
GOOD JENNIFER L
President & CEO
Sep 04 '24
Sale
3.02
10,981
33,205
213,313
GOOD JENNIFER L
President & CEO
Sep 03 '24
Sale
3.02
3,863
11,677
213,313
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):